Extravasation of oxaliplatin: an infrequent and irritant toxicity

Oxaliplatin has been classified as an irritant drug. Less than 10 cases of oxaliplatin extravasation through a central venous access have been described to date. We present a case of extravasation through a central venous access, of the highest dose (165 mg) of oxaliplatin reported to date. We confi...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2009-02, Vol.11 (2), p.114-116
Main Authors: Pericay, Carles, López, Anna, Soler, Joan Ramón, Bonfill, Teresa, Dotor, Emma, Saigí, Eugeni
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Case Reports
Extravasation of Diagnostic and Therapeutic Materials - diagnosis
Extravasation of Diagnostic and Therapeutic Materials - pathology
Extravasation of Diagnostic and Therapeutic Materials - therapy
Female
Humans
Medicine
Medicine & Public Health
Oncology
Organoplatinum Compounds - administration & dosage
Organoplatinum Compounds - adverse effects
Rectal Neoplasms - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oxaliplatin has been classified as an irritant drug. Less than 10 cases of oxaliplatin extravasation through a central venous access have been described to date. We present a case of extravasation through a central venous access, of the highest dose (165 mg) of oxaliplatin reported to date. We confirmed the irritant effect, and full recovery from toxicity was achieved. We describe the treatment administered and offer a review of literature.
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-009-0324-z